Has Jonathan Rosenberg, MD received payments from drug or device companies?

Yes. Drug and device makers reported $179,869 in general payments to Jonathan Rosenberg, MD across 174 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jonathan Rosenberg, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jonathan Rosenberg, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jonathan Rosenberg, MD

Medical Oncology · New York, NYNPI 1942268073

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $126,723 of the $179,869 with a category attached, or 70.5%. 25 manufacturers reported payments, led by Seagen Inc. at 24.5% of the total. Reporting peaked in 2022 at $45,984 and has fallen 67.8% since, to $14,809 in 2025. Among medical oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$179,869in general payments, 2019–2025

Across 174 payments — averaging $1033.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Seagen Inc.$44K
Pfizer$25K
E.r. Squibb & Sons, L.L.C.$12K
Astrazeneca UK Limited$12K
Genentech, Inc.$12K
EMD Serono, Inc.$10K
plus $65K from 19 others

$3,648,992in research payments, 2019–2025

Across 291 payments — averaging $12,539 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Seagen Inc.$1.8M
Genentech, Inc.$613K
Astellas Pharma Global Development$499K
Eli Lilly$471K
AstraZeneca$97K
Pfizer$76K
plus $66K from 4 others

What the payments were for

Consulting fees$126,72370%
Speaking & faculty fees$33,67719%
Travel & lodging$14,5728%
Food & beverage$4,8973%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Seagen Inc.	33	$44,026
Pfizer	29	$25,179
E.r. Squibb & Sons, L.L.C.	24	$12,279
Astrazeneca UK Limited	7	$11,927
Genentech, Inc.	5	$11,567
EMD Serono, Inc.	3	$10,365
GSK	7	$9,855
Gilead	13	$8,878
Astellas Pharma Global Development	4	$7,465
Boehringer Ingelheim International GmbH	4	$7,326
Janssen Global Services, LLC	11	$5,854
AstraZeneca	8	$4,623
F. Hoffmann-la Roche AG	7	$4,244
Aadi Bioscience, Inc.	1	$3,600
Merck	3	$3,264
Astellas Pharma US Inc	1	$2,275
Eli Lilly	2	$1,933
Bayer	3	$1,750
EMD Serono Research & Development Institute, Inc.	1	$1,500
Samsung Bioepis Co., Ltd.	2	$1,110
Bristol Myers Squibb	1	$600
La Jolla Pharmaceutical Company	1	$128
Lilly USA, LLC	2	$50
Johnson & Johnson	1	$43
Exelixis Inc.	1	$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PADCEV$40,753
TECENTRIQ$15,586
BAVENCIO$11,365
Trodelvy$8,568
IMFINZI$4,920
FYARRO$3,600
Balversa$3,100
OPDIVO$2,588
E303$1,040
IMJUDO$927
XTANDI$136
ORGOVYX$136
TALZENNA$136
Xerava$128
Zevtera$128
XACDURO$128
GIAPREZA$128
LYNPARZA$107

How this compares

$179,869 in reported general payments places this provider in the 90th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024

$85,778

Medicare patients

106

Services billed

860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ondansetron Hcl	33	$239
Tamsulosin Hcl	16	$217
Dexamethasone	13	$169
Omeprazole	13	$156
Triamcinolone Acetonide	15	$155
Levothyroxine Sodium	11	$89
Metformin Hcl ErMetformin Hcl	14	$22

Paid to pharmacies, not to this prescriber.

Other medical oncology in New York

Craig ThompsonNew York$4.8M
Andrew SeidmanNew York$1.3M
Joshua RichterNew York$971K
Edward GelmannNew York$944K
Ghassan Abou-AlfaNew York$825K
Miguel PeralesNew York$769K
Komal JhaveriNew York$642K
Joshua BrodyNew York$492K
Aiwu HeNew York$445K
Raajit RampalNew York$418K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →